-1768251123750.webp&w=3840&q=75)
2025 MaTOS Lung | Session III | Challenging Cases | Early-Stage NSCLC Case-Based Panel Discussion
Overview
Dr. Nagasaka presented Case 1, a 63-year-old with EGFR-mutant stage IIB NSCLC highlighted adjuvant chemo plus osimertinib and debate on continuing therapy beyond three years.
Dr. Iams presented Case 2, a 64-year-old with large lung adenocarcinoma revealed rare EZH1 fusion on NGS; panel favored trials or targeted therapy given high recurrence risk.
Dr. Doroshow reviewed Case 3, a 60-year old woman who showed early-stage lung adenocarcinoma treated with neoadjuvant IO and surgery, later recurring. Discussion stressed EGFR biology, MRD testing, and role of radiation.
Dr. Rodriguez presented Case 4, a 46-year-old with stage IIIB BRAF-mutant NSCLC showed major pathologic response after chemo; panel favored adjuvant immunotherapy and discussed local control.
Dr. Iams presented Case 2, a 64-year-old with large lung adenocarcinoma revealed rare EZH1 fusion on NGS; panel favored trials or targeted therapy given high recurrence risk.
Dr. Doroshow reviewed Case 3, a 60-year old woman who showed early-stage lung adenocarcinoma treated with neoadjuvant IO and surgery, later recurring. Discussion stressed EGFR biology, MRD testing, and role of radiation.
Dr. Rodriguez presented Case 4, a 46-year-old with stage IIIB BRAF-mutant NSCLC showed major pathologic response after chemo; panel favored adjuvant immunotherapy and discussed local control.
Target Audience
Physicians
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Moderator: Mark G. Kris, MD
Speakers and Panelists:
Misako Nagasaka, MD, PhD
Wade T. Iams, MD, MSCI
Deborah Doroshow, MD, PhD
Estelamari Rodriguez, MD, MPH
Panelists:
David Carbone, MD, PhD
Puneeth Iyengar, MD, PhD
Date of Release
January 8th, 2026
-1769196766441.webp&w=3840&q=75)
-1769196674841.webp&w=3840&q=75)